UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	FORM 8-K	
	CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934	
	May 17, 2023 Date of Report (date of earliest event reported)	
	JUSHI HOLDINGS INC.	
	(Exact name of registrant as specified in its charter)	
British Columbia	000-56468	98-1547061
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
	301 Yamato Road, Suite 3250 Boca Raton, FL 33431	
	(Address of principal executive offices and zip code)	
	(561) 617-9100	
	(Registrant's telephone number, including area code))
Check the appropriate box below if the Form 8-K fi provisions:	ling is intended to simultaneously satisfy the filing obligat	ion of the registrant under any of the following
☐ Written communications pursuant to Rul	e 425 under the Securities Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-1	2 under the Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pur	suant to Rule 14d-2(b) under the Exchange Act (17 CFR 2	240.14d-2(b))
☐ Pre-commencement communications pur	suant to Rule 13e-4(c) under the Exchange Act (17 CFR 2	40.13e-4(c))
	Securities registered pursuant to Section 12(b) of the A	ct:
Title of each class	Trading Symbol	Name of each exchange on which registered
None	N/A	N/A
Indicate by check mark whether the registrant is an 12b-2 of the Securities Exchange Act of 1934 (§240.1	emerging growth company as defined in Rule 405 of the S2b-2 of this chapter).	Securities Act of 1933 (§230.405 of this chapter) or Rule
Emerging growth company ⊠		
If an emerging growth company, indicate by check in financial accounting standards provided pursuant to	mark if the registrant has elected not to use the extended to Section 13(a) of the Exchange Act. \Box	transition period for complying with any new or revised

Item 7.01. Regulation FD Disclosure.

On May 17, 2023, Jushi Holdings Inc. released an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information disclosed pursuant to this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Investor Presentation of Jushi Holdings Inc., dated May 17, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

May 17, 2023

JUSHI HOLDINGS INC.

By: /s/ Jon Barack

Jon Barack President



The Next Generation Cannabis Platform

Cautionary Statement Regarding Forward-Looking Statements

This presentation contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation as well as statements that may constitute "forward-looking statements" within the meaning of within the meaning of the Private Securities Litigation Reform Act of 1934, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, intended expansion of our retail operations and production capacity, intended expansion of our cultivation facilities, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. These forward-looking statements are based on Jushi's current expectations and beliefs concerning future developments and their potential effects. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not expect," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases or may contain statements that certain actions, events or results "may," "could," "would," "might" or "will be taken," "will continue," and expectations for other economic, business, and/or competitive factors. Many factors could cause actual future events to differ materially from the forward-looki

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Operational Results Advisory

Any statements regarding the Company's estimated operations following Q1 2023 do not present all information necessary for an understanding of the Company's current or future results of operations and undue reliance should not be placed on such estimates, all of which are "forward-looking information" and "forward-looking statements" subject to the risks and uncertainties described above.

Primary Drivers for 2023



MARGIN GROWTH, COST SAVINGS & EFFICIENCY OPTIMIZATION

Grower-Processors

- Full production output
- · Increasing plant yields, turns, potency and improved genetics

Retail

- Reducing costs
- Increasing efficiencies
- Augmenting online digital orders

Balance Sheet

- Optimizing balance sheet
- Preserving cash



Targeting Positive Operating Cash Flow by Q4 2023

Jushi's Portfolio of Assets – May 2023

NUMBER OF OPERATING STORES*

Total	PA	VA	MA	NV	ОН	IL	CA
34 (of 38) ⁽¹⁾	16 (of 18)**	5 (of 6) ⁽¹⁾	2	4	1	4***	2 (of 3)****

CULTIVATION & PROCESSING FACILITIES

Total	PA	VA	MA	NV	ОН	IL	CA
5	Yes	Yes	Yes	Yes	Yes		
330k sq. ft.	123k sq. ft.	93k sq. ft.	50k sq. ft.	47k sq. ft.	17k sq. ft.		

Operating Markets

Operating Vertical Markets

~1,198 Jushi Employees*****

^{*} As of the beginning of May 2023

^{**} Includes store closures in Colwyn, PA, and Hazleton, PA in April 2023. The Colwyn , PA and Hazleton, PA stores will be relocated to other locations within their permit region, subject to regulatory approvals.

^{***} Excludes one conditional license awarded in the Greater Peoria Region, IL
**** Excludes one conditional license awarded in Culver City, CA

^{*****} As of April 2023



PRIMARY MARKET DRIVERS



Scan to see more about Pennsylvania on your phone. https://jushico.com/pa-highlights

Vertically Integrated with 16 (of 18)* Medical Dispensaries (out of $\sim 175^{(2)}$; $\sim 10\%$ of market)

16 (of 18)*

Dispensaries

~123k

Sq. Ft. Facility

11

Flower Rooms

~13M

PA Population⁽³⁾

899k


Market Patients & Caregivers⁽⁴⁾ (6.9% of Pop)


425k

Market Active Patients⁽⁵⁾ (3.3% of Pop)

* Colwyn and Hazleton stores closed in April 2023 and will be relocated to other locations within their permit region, subject to regulatory approvals.







The Jushi Retail Experience

LEADING OMNICHANNEL EXPERIENCE

Jushi provides patients and customers with a frictionless retail experience.



Retail Design

Our carefully designed and inviting cannabis experience welcomes all levels of consumers.



Digital

Place your order online for express pickup, curbside or delivery and download our app for exclusive savings. Available in select markets.



Products

We offer our customers an expansive variety of house products across all major categories and price points.

ò

Next-Level Store Design

LEADING OMNICHANNEL EXPERIENCE




- Sleek Mid-Century Design
- Ample Parking
- Great Signage
- Express Pickups Where Permitted



- Built for Medical or Adult-use
- Multiple Points of Sale
- UX In-Store Design
- Beyond TV

10



Hello Club - Rewards App

JUSHI'S LEADING OMNICHANNEL EXPERIENCE

The Hello Club app provides our valued customers with a rewards program, in-app shopping and weekly app-exclusive deals. It's our most valuable retention tool.

~64k

Downloads (As of 3/31/23)

~\$60*

Additional Monthly Spend / App User (9)





Scan to download our app on your phone.

https://jushico.com/thc-app

*As of 3/31/23 and not including Pennsylvania data





Comprehensive Suite of Brands Across Portfolio

JUSHI'S LEADING OMNICHANNEL EXPERIENCE



FLOWER VAPE & CONCENTRATE EDIBLES & TOPICAL





PACKAGED FLOWER (LAUNCHING 2023)







PACKAGED FLOWER

ZEPHE STEEL CONTRACTOR

PACKAGED FLOWER & PRE-ROLLS









SOLVENTLESS, LIVE RESIN & CURED CARTRIDGES, DISPOSABLES & CONCENTRATES

TASTEOLOGY



INFUSED CHEWS & CHOCOLATES





TINCTURES & CAPSULES

13

Primary Markets Regulatory Updates

•

Pennsylvania

- Governor Shapiro is considered hands-on and looking to drive policy
 - On record as supporting an adult-use market (10)
 - Former Attorney General and is actively appointing both Republicans and Democrats to key positions in his administration
- Members of both the House and Senate are in active conversations about adult-use legislation
 - Multiple bills thought to be under consideration
- Governor Shapiro has an adult-use line item in the PA budget starting no later than $1/1/25\,{}^{(11)}$
- New leadership within DOH continues to allow for growth in current market (12)

Primary Markets Regulatory Updates

•

Virginia

- Continue to see positive progression for the Medical Cannabis Program
 - Patient Growth expected to continue in 2023 with medical clean-up bill
 - No new licenses for medical program
 - Transition from Board of Pharmacy to Cannabis Control Authority 1/1/24
 - Hemp regulation implementation
- Existing government leadership continues to be a hurdle for implementation of adult-use
 - Major turnover in both the House and Senate coming in November election
 - 30% of Senate and 40% of House retiring

Appendix

Jushi Leadership Team



Jim Cacioppo CEO, Chairman & Founder



Jon BarackPresident & Founder



Michelle Mosier Chief Financial Officer



Tobi Lebowitz Chief Legal Officer & Corporate Secretary



Nichole Upshaw Chief People Officer

17

Q1 2023 - Strong Top Line and Expanding Margin Profile

Scan to check out the

<u>Financials and Filings :: Jushi Holdings Inc.</u> (JUSH) (jushico.com)


latest financials now on your phone!

US\$ Millions, prepared under U.S. GAAP

Revenue



Gross Margin



Capitalization Summary



(Amounts in millions)	March 31, 2023
Cash ⁽¹⁾	\$19.4
Total Debt ⁽²⁾	\$209.0
Net Debt	\$189.6
	May 8, 2023
Subordinate Voting Shares Outstanding	196,633,371
Options	28,098,758(3)
Warrants	85,948,837 ⁽⁴⁾
Fully Diluted Shares Outstanding	310,680,966

Debt

 Priority to reduce debt level and optimize debt terms

Capital Expenditures

- ~\$4.5MM for Q1 2023
- FY 2023, expected CapEx for new projects to be ~\$13.0 M, of which ~\$6.0 M is discretionary

(1) As of March 30, 2023, includes cash, cash equivalents, and restricted cash; (2) As of March 30, 2023, excluding leases and property, plant and equipment financing obligations; (3) Weighted Average Strike Price: \$2.47; (4) Weighted Average Strike Price: \$1.50

Adjusted EBITDA Reconciliation





		Three Months Ended March 31,		
	*	2023		2022
NET LOSS ⁽¹⁾	S	(12,440)	\$	(19,757)
Income tax expense	W	10,148		5,051
Interest expense, net		8,520		10,116
Depreciation and amortization (2)		7,335		3,248
EBITDA (Non-GAAP)	\$	13,563	\$	(1,342)
Non-cash share-based compensation		2,311		6,964
Inventory-related adjustments (3)		251		3,742
Fair value changes in derivatives		(8,030)		(14,309)
Other (income) expense, net ⁽⁴⁾		(511)		575
Start-up costs ⁽⁵⁾	163	_		2,715
Transaction costs (6)		19		780
Adjusted EBITDA (Non-GAAP)	S	7,603	\$	(875)

- Net loss includes amounts attributable to non-controlling interests.
- (2) Includes amounts that are included in cost of goods sold and in operating expenses.
- (3) Includes: (i) inventory step-up on business combinations; (ii) inventory recall reserves; and (iii) reserves for discontinued products. The inventory step-up on business combinations relate to the fair value write-up on inventory acquired on the business acquisition date and then sold subsequent to the acquisition date. The inventory recall reserves relate to the estimated impact of the Pennsylvania Department of Health recall and ban of vape products containing certain cannabis concentrates. The ban was lifted in June 2022.
- (4) Includes: (i) remeasurement of contingent consideration related to acquisitions; (ii) losses (gains) on legal settlements; and (iii) severance costs.
- (5) Expansion and start-up costs incurred in order to prepare a location for its intended use. Start-up costs are expensed as incurred and are not indicative of ongoing operations of each new location.
- (6) Transaction costs include: (i) registration statement costs such as professional fees and other costs relating to our SEC registration; and (ii) acquisition and deal costs.

20



JUSHI HOLDINGS INC. Reconciliation of Non-GAAP Financial Measures

EBITDA and Adjusted **EBITDA**

In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. We use non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. These non-GAAP financial measures are EBITDA and Adjusted EBITDA (leach as defined below). We believe that these non-GAAP financial measures reflect our ongoing business by excluding the effects of expenses that are not reflective of our operating business performance and allow for meaningful comparisons and analysis of trends in our business. These non-GAAP financial measures also facilitate comparing financial results across accounting periods and to those of peer companies. As there are no standardized methods of calculating these non-GAAP measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness. Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

EBITDA and Adjusted EBITDA are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or "earnings", before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as set income (loss), or "earnings", before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) non-cash share-bossed compensation expense and other one-time charges; (ii) inventory-related adjustments; (iii) fair value changes in derivatives; (iv) other (income)/expense items; (v) transaction costs; (vi) osset impairment; (vii) loss on debt extinguishment; and (viii) start-up costs. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannobis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

Disclaimers

NO OFFER

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

THIRD PARTY INFORMATION

This presentation may include market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

REGULATORY

Potential investors are aware that the cannobis market is highly regulated, and that various permits and outhorizations are necessary for the import, distribution, sale or other business activities related to medicinal cannobis. The respective regulations can be subject to change, which might affect the permits required. This presentation does not intend to advertise the products of the Company. Any reference to the products serves only the information of potential investors and shall not incite the purchase of the products.

COPYRIGHT

All brands and trademarks mentioned in this presentation and possibly protected by third parties are subject without restriction to the provisions of the applicable trademark law and the ownership rights of the respective registered owners. The mere fact that a trademark is mentioned should not lead to the conclusion that it is not protected by the rights of third parties. The copyright for published objects created by the Company remains solely with the Company. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without the Company's agreement.

CURRENCY

All references to \$ or "dollar" in this presentation are references to USD, unless otherwise indicated.

Endnotes

- (1) Jushi plans to open one additional dispensary in Virginia subject to regulatory approvals.
- (2) (Number of Pennsylvania dispensaries) https://www.health.pa.gov/topics/Documents/Programs/Medical%20Marijuana/Medical%20Marijuana%20Dispensaries%20in%20Pennsylvania%20with%20Product.pdf
- (3) (Population) https://www.census.gov/quickfacts/PA
- (4) (5) (Pennsylvania Patients & Caregivers and Active Patients) https://www.health.pa.gov/topics/Documents/Programs/Medical%20Marijuana/MMAB%20Presentation%20for%20April%2012,%202023.pdf
- (6) (Virginia State Population) https://www.census.gov/quickfacts/VA
- (7) (HSA II Population) https://www.census.gov/quickfacts/alexandriacityvirginia, alexandriacityvirginia, alexandriacityvirginia, alexandriacityvirginia, processis, fact/table/princevilliamcountyvirginia, ananassascityvirginia, fairfaxcountyvirginia, arlingtoncountyvirginia, alexandriacityvirginia, alexandri
- (8) (Jushi's total number of certified patients in Jushi's HSA II footprint since May 2023). Total Jushi certified patients that have ordered and purchased in last 12 months within HSA II". Virginia does not provide state level patient counts.
- (9) Data is sourced from Springbig which doesn't include PA data app users
- (10) (Governor Shapiro on record for supporting an adult-use market) https://www.abc27.com/pennsylvania-will-pennsylvania-will-pennsylvania-governor-josh-shapiro/;
 <a href="https://www.wilf.org/2022/10/14/pa-election-2022-where-doug-mastriano-josh-shapiro-stand-on-the-opioid-epidemic-medical-marijuana-and-other-health-issues/; https://www.marijuanamoment.net/pennsylvania-governors-race-exposes-marijuana-divide-between-pro-legalization-ag-and-gop-senator-who-called-reform-stupid-ideo/; https://wwitter.com/joshShapiroPA/status/1507139146300723203; https://www.phillyvoice.com/pennsylvania-marijuana-legalization-shapiro-2023-recreational-bipartisan-bill/; https://www.inquirer.com/news/marijuana-laws-mastriano-shapiro-decriminalization-20221007.html
- (11) (Governor Shapiro includes cannabis in budget proposal) https://www.spotlightpa.org/news/2023/05/pa-josh-shapiro-budget-public-health-covid-black-maternal-health-cannabis/#:~:text=Democratic%20Gov.%20Josh%20Shapiro's%20budget%20proposed%20a%2020%25%20tax%20adult,dollar%20amounts%20are%20in%20millions.&text=%24188.8-,Dates%20refer%20to%20when%20the%20fiscal%20years%20end,it%20June%20of%20each%20year.
- (12) [PA DOH continues to allow for growth in current market) https://www.health.pa.gov/topics/programs/Medical%20Marijuana/Pages/Medical%20Marijuana.aspx; https://www.legis.state.pa.us/cfdocs/billinfo/bill_history.cfm?syear=2023&sind=0&body=5&type=8&bn=538

